• Something wrong with this record ?

A Multicenter Study of Stellate Ganglion Block as a Temporizing Treatment for Refractory Ventricular Arrhythmias

F. Chouairi, K. Rajkumar, A. Benak, Y. Qadri, JP. Piccini, J. Mathew, ND. Ray, J. Toman, J. Kautzner, A. Ganesh, M. Sramko, M. Fudim

. 2024 ; 10 (4) : 750-758. [pub] 20240214

Language English Country United States

Document type Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc24014476

BACKGROUND: Ventricular tachycardia (VT) and ventricular fibrillation (VF) are life-threatening conditions and can be refractory to conventional drug and device interventions. Stellate ganglion blockade (SGB) has been described as an adjunct, temporizing intervention in patients with refractory ventricular arrhythmia. We examined the association of SGB with VT/VF in a multicenter registry. OBJECTIVES: This study examined the efficacy of SGB for treatment/temporization of refractory VT/VF. METHODS: The authors present the first analysis from a multicenter registry of patients treated for refractory ventricular arrhythmia at a clinical site in the Czech Republic and the United States. Data were collected between 2016 and 2022. SGB was performed at the bedside by anesthesiologists and/or cardiologists. Outcomes of interest were VT/VF burden and defibrillations at 24 hours before and after SGB. RESULTS: In total, there were 117 patients with refractory ventricular arrhythmias treated with SGB at Duke (n = 49) and the Institute for Clinical and Experimental Medicine (n = 68). The majority of patients were male (94.0%), were White (87.2%), and had an implantable cardioverter-defibrillator (70.1%). The most common etiology of heart disease was ischemic cardiomyopathy (52.1%), and monomorphic VT was the most common morphology (70.1%). Within 24 hours before SGB (0-24 hours), the median episodes of VT/VF were 7.5 (Q1-Q3: 3.0-27.0), and 24 hours after SGB, the median decreased to 1.0 (Q1-Q3: 0.0-4.5; P < 0.001). At 24 hours before SGB, the median defibrillation events were 2.0 (Q1-Q3: 0.0-8.0), and 24 hours after SGB, the median decreased to 0.0 (Q1-Q3: 0.0-1.0; P < 0.001). CONCLUSIONS: In the largest cohort of patients with treatment-refractory ventricular arrhythmia, we demonstrate that SGB use was associated with a reduction in the ventricular arrhythmia burden and need for defibrillation therapy.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24014476
003      
CZ-PrNML
005      
20240905134326.0
007      
ta
008      
240725s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jacep.2023.12.012 $2 doi
035    __
$a (PubMed)38363278
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Chouairi, Fouad $u Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA
245    12
$a A Multicenter Study of Stellate Ganglion Block as a Temporizing Treatment for Refractory Ventricular Arrhythmias / $c F. Chouairi, K. Rajkumar, A. Benak, Y. Qadri, JP. Piccini, J. Mathew, ND. Ray, J. Toman, J. Kautzner, A. Ganesh, M. Sramko, M. Fudim
520    9_
$a BACKGROUND: Ventricular tachycardia (VT) and ventricular fibrillation (VF) are life-threatening conditions and can be refractory to conventional drug and device interventions. Stellate ganglion blockade (SGB) has been described as an adjunct, temporizing intervention in patients with refractory ventricular arrhythmia. We examined the association of SGB with VT/VF in a multicenter registry. OBJECTIVES: This study examined the efficacy of SGB for treatment/temporization of refractory VT/VF. METHODS: The authors present the first analysis from a multicenter registry of patients treated for refractory ventricular arrhythmia at a clinical site in the Czech Republic and the United States. Data were collected between 2016 and 2022. SGB was performed at the bedside by anesthesiologists and/or cardiologists. Outcomes of interest were VT/VF burden and defibrillations at 24 hours before and after SGB. RESULTS: In total, there were 117 patients with refractory ventricular arrhythmias treated with SGB at Duke (n = 49) and the Institute for Clinical and Experimental Medicine (n = 68). The majority of patients were male (94.0%), were White (87.2%), and had an implantable cardioverter-defibrillator (70.1%). The most common etiology of heart disease was ischemic cardiomyopathy (52.1%), and monomorphic VT was the most common morphology (70.1%). Within 24 hours before SGB (0-24 hours), the median episodes of VT/VF were 7.5 (Q1-Q3: 3.0-27.0), and 24 hours after SGB, the median decreased to 1.0 (Q1-Q3: 0.0-4.5; P < 0.001). At 24 hours before SGB, the median defibrillation events were 2.0 (Q1-Q3: 0.0-8.0), and 24 hours after SGB, the median decreased to 0.0 (Q1-Q3: 0.0-1.0; P < 0.001). CONCLUSIONS: In the largest cohort of patients with treatment-refractory ventricular arrhythmia, we demonstrate that SGB use was associated with a reduction in the ventricular arrhythmia burden and need for defibrillation therapy.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    12
$a ganglion stellatum $7 D013233
650    12
$a komorová tachykardie $x terapie $7 D017180
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    12
$a fibrilace komor $x terapie $7 D014693
650    12
$a blokáda autonomních nervů $x metody $7 D001340
650    _2
$a registrace $7 D012042
650    _2
$a defibrilátory implantabilní $7 D017147
650    _2
$a výsledek terapie $7 D016896
650    _2
$a dospělí $7 D000328
651    _2
$a Česká republika $7 D018153
651    _2
$a Spojené státy americké $7 D014481
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Rajkumar, Karuna $u Wake Forest Baptist Health, Winston Salem, North Carolina, USA
700    1_
$a Benak, Ales $u Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Qadri, Yawar $u Emory University Hospital, Atlanta, Georgia, USA
700    1_
$a Piccini, Jonathan P $u Division of Cardiology, Department of Internal Medicine, Duke University School of Medicine, Durham, North Carolina, USA; Duke Clinical Research Institute, Durham, North Carolina, USA
700    1_
$a Mathew, Joseph $u Division of Anesthesia, Duke University School of Medicine, Durham, North Carolina, USA
700    1_
$a Ray, Neil D $u Division of Anesthesia, Duke University School of Medicine, Durham, North Carolina, USA
700    1_
$a Toman, Jakub $u Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Kautzner, Josef $u Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Ganesh, Arun $u Division of Anesthesia, Duke University School of Medicine, Durham, North Carolina, USA
700    1_
$a Sramko, Marek $u Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Fudim, Marat $u Division of Cardiology, Department of Internal Medicine, Duke University School of Medicine, Durham, North Carolina, USA; Duke Clinical Research Institute, Durham, North Carolina, USA. Electronic address: Marat.fudim@duke.edu
773    0_
$w MED00193518 $t JACC. Clinical electrophysiology $x 2405-5018 $g Roč. 10, č. 4 (2024), s. 750-758
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38363278 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905134319 $b ABA008
999    __
$a ok $b bmc $g 2143933 $s 1226342
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 10 $c 4 $d 750-758 $e 20240214 $i 2405-5018 $m JACC. Clinical electrophysiology $n JACC Clin Electrophysiol $x MED00193518
LZP    __
$a Pubmed-20240725

Find record

Citation metrics

Archiving options